Michael Rosenblatt, MD, Chief Medical Officer at Flagship Pioneering
Overview
Inventing a drug is one of the most challenging, expensive and prolonged initiatives that is undertaken in the life sciences. The definition of a “drug” is changing dramatically and is now much broader than small molecules and biologics. This calls for both different discovery and development approaches, and enhanced collaboration across the biopharmaceutical industry, government and academia. In this webinar, Dr. Michael Rosenblatt, Chief Medical Officer at Flagship Pioneering (and former Chief Medical Officer at Merck) discusses novel, innovative approaches to drug invention and how they complement established approaches.
About the Presenter
Michael Rosenblatt, MD is a physician-scientist, whose career spans academia, pharma and biotech/venture. He is the Chief Medical Officer of Flagship Pioneering in Cambridge, MA, a firm that originates new biotech companies. Previously, he was Merck’s first Chief Medical Officer. He also served as Dean of Tufts University School of Medicine, and before that, Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. During his first period at Merck, he co-led development of alendronate (FOSAMAX) for osteoporosis. He received the Fuller Albright Award, the Vincent du Vigneaud Award and Merck’s Chairman’s Award. Active in biotechnology, he was a founder of ProScript, which discovered bortezomib (Velcade) for multiple myeloma, and Radius, which developed abaloparatide (Tymlos) for osteoporosis.